Why is Mangalam Drugs falling/rising?

As of 21-Jul, Mangalam Drugs and Organics Ltd is experiencing a price increase, currently at Rs 88.61, reflecting a rise of Rs 3.09 or 3.61%. The stock has shown positive momentum, gaining 3.94% over the last two days and outperforming its sector by 3.93% today. Despite a year-to-date decline of 23.58%, the stock has performed well in the short term, with a 12.16% increase over the past month. The company's valuation appears attractive, with a return on capital employed (ROCE) of 8.6% and a PEG ratio of 0.1, indicating that it is trading at a discount compared to its peers. However, the stock has also faced challenges, including a significant drop in profit after tax and net sales in the last quarter, which fell by 97.6% and 15.9%, respectively.
In the broader market context, the stock's recent performance contrasts with the benchmark Sensex, which has seen a slight decline of 0.06% over the past week. While Mangalam Drugs has outperformed the benchmark in the short term, it has consistently underperformed over the longer term, with a 39.33% decline over the past three years compared to the Sensex's 47.62% gain. This underperformance, coupled with a high debt-to-EBITDA ratio and low return on equity, suggests that while the stock may be experiencing a temporary rise, its long-term fundamentals remain weak, indicating potential risks for investors.